Beroni Group Received Approval for 43.5% R&D Rebate from Australian Government for the Novel, Potential Anti-Cancer Drug PENAO

Stock Information for Beroni Group Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Beroni Group Limited

Beroni Group's Enhanced COVID-19 Antigen Rapid Test Kit Received CE Certification
Beroni Group Announces Appointment of Dr. John Chiplin to Board of Directors
Beroni Group to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT
Beroni Group Sets Up a New R&D Centre in High-Tech Hub in Zhuhai, China
Beroni Group Received a US$1.07 Million Order for COVID-19 Antigen Test Kits from Japan
Beroni Group Published an Article Related to Single-Domain Antibodies in the FEBS Journal
Beroni Group Announced the Latest Clinical Study of its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method)
Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.